NORFLOXACIN 400 MG
NORFLOXACIN : 400 MG · DIN 02229524 · AA PHARMA INC
Health Canada status: MARKETED
What is NORFLOXACIN?
NORFLOXACIN 400 MG contains NORFLOXACIN : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02229524, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Sep-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NORFLOXACIN used for?
Upper and lower urinary tract infections (cystitis, pyelitis, pyelonephritis) caused by susceptible strains; gonococcal urethritis or cervicitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02229524 |
|---|---|
| Brand name | NORFLOXACIN |
| Generic / active ingredient | NORFLOXACIN : 400 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 400 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01MA06 NORFLOXACIN |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Sep-2018 |
| Original market date | 1998-07-20 00:00:00 |
How is it administered?
UTI: 400 mg twice daily for 7-10 days (3 days for uncomplicated cystitis). Gonorrhea: 800 mg single dose. Take 1 hour before or 2 hours after meals/milk.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), typically room temperature.
How is it supplied?
Bottles of 100, 500 and 1000 tablets.
Contraindications
Hypersensitivity to norfloxacin or other quinolone antibacterial agents.
Warnings and precautions
Disabling/persistent reactions (tendonitis, neuropathy, neuropsychiatric); QT prolongation; exacerbation of myasthenia gravis; aortic aneurysm risk; blood glucose disturbances.
Is NORFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA06 NORFLOXACIN. 1 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AVA-NORFLOXACIN | 400 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02366304 |
| CO NORFLOXACIN | 400 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | DIN 02269627 |
| NORFLOXACIN | 400 MG | TABLET | PHARMEL INC | CANCELLED PRE MARKET | DIN 02246937 |
| NORFLOXACIN | 400 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | DIN 02344882 |
| NORFLOXACINE-400 | 400 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239670 |
| NOROXIN | 400 MG | TABLET | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00643025 |
| NTP-NORFLOXACIN | 400 MG | TABLET | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02364298 |
| PMS-NORFLOXACIN | 400 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02246596 |
| RIVA-NORFLOXACIN | 400 MG | TABLET | LABORATOIRE RIVA INC. | CANCELLED POST MARKET | DIN 02301504 |
| RIVA-NORFLOXACIN | 400 MG | TABLET | LABORATOIRE RIVA INC. | CANCELLED POST MARKET | DIN 02241483 |
Who else supplies NORFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NORFLOXACIN appears in 24 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.